Hyperpigmentation disorder treatment Market Share Analysis Report, 2023-2032
The global hyperpigmentation disorder treatment market size was valued at USD 4.3 billion in 2022 and is predicted to be worth USD 9.5 billion by 2032, with a CAGR of 8.5% from 2023 to 2032.
Key Pointers:
Pigmentation refers to areas of the skin that have darkened in color compared to the surrounding skin, often resulting in a patchy or uneven appearance. Pigmentation can appear as freckles and sunspots, melasma or chloasma, seborrheric keratosis, and birthmarks. It can be exacerbated by the usage of inappropriate skin care products as well as continued sun exposure and heat trauma. Hyperpigmentation occurs when melanocytes in the deeper layers of the skin produce melanin, a skin-darkening pigment. Melanin overproduction can result in darker skin patches on the skin's surface. Skin hypopigmentation is caused by a decrease in melanin production. Hyperpigmentation disorders can be treated with cosmeceuticals, laser treatment, and chemical peels. Furthermore, rise in prevalence of melasma and increase in awareness about hyperpigmentation treatment are driving the global hyperpigmentation disorders treatment market size.
Hyperpigmentation is quite common and relatively harmless. It could be a source of embarrassment for those who suffer from it. Hyperpigmentation, or a dark pigmentation patch on the face, causes an abnormally high concentration of skin pigments responsible for the production of melanocytes. Hyperpigmentation is most common in Mediterranean, Asian, African, and Latino populations.
Hyperpigmentation is a widespread and serious skin condition that affects people of all skin types. Despite the availability of various depigmentation active ingredients for skin hyperpigmentation disorders, none are completely satisfactory due to poor permeability through the skin layer and significant toxicity, resulting in severe side effects such as irritant dermatitis, erythema, itching, and skin flaking. Nanotechnology plays an important role in advancing cosmeceutical formulation by improving active ingredient solubility, stability, safety, loading efficiency, and dermal permeability.
Hyperpigmentation disorder treatment Market Segmentation
| Treatment Type | Disease Indication | End-user |
|
Cosmeceuticals Laser Therapy Chemical Peels Microdermabrasion Phototherapy Others
|
Melasma Post-inflammatory Hyperpigmentation Solar Lentigines Others |
Hospitals Esthetic Clinics & Dermatology Centers Others |
Hyperpigmentation disorder treatment Market Key Players And Regions
| Companies Profiled | Regions Covered |
|
Aerolase Corporation Candela Corporation Cynosure Galderma S.A. iSCLINICAL ISDIN L'Oréal (SkinCeuticals, Skinbetterscience & La Roche-Posay) LumenisBe Ltd. Mesoestetics Obagi Cosmeceuticals LLC PCA Skin Scientis Senté SkinMedica (AbbVie) SoltaMedical ZO Skin Health, Inc. |
North America Latin America Europe Asia Pacific Middle East & Africa |
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Healthcare API Market
5.1. COVID-19 Landscape: Healthcare API Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Healthcare API Market, By Service
8.1. Healthcare API Market, by Service, 2022-2030
8.1.1 Remote Patient Monitoring
8.1.1.1. Market Revenue and Forecast (2022-2032)
8.1.2. Payment
8.1.2.1. Market Revenue and Forecast (2022-2032)
8.1.3. EHR Access
8.1.3.1. Market Revenue and Forecast (2022-2032)
8.1.4. Appointments
8.1.4.1. Market Revenue and Forecast (2022-2032)
8.1.5. Wearable Medical Devices
8.1.5.1. Market Revenue and Forecast (2022-2032)
Chapter 9. Global Healthcare API Market, By Deployment Model
9.1. Healthcare API Market, by Deployment Model, 2022-2030
9.1.1. Cloud-Based API
9.1.1.1. Market Revenue and Forecast (2022-2032)
9.1.2. On Premise-Based API
9.1.2.1. Market Revenue and Forecast (2022-2032)
Chapter 10. Global Healthcare API Market, By End-Use
10.1. Healthcare API Market, by End-Use, 2022-2030
10.1.1. Patients
10.1.1.1. Market Revenue and Forecast (2022-2032)
10.1.2. Healthcare Providers
10.1.2.1. Market Revenue and Forecast (2022-2032)
10.1.3. Healthcare Payers
10.1.3.1. Market Revenue and Forecast (2022-2032)
10.1.4. Vendors
10.1.4.1. Market Revenue and Forecast (2022-2032)
Chapter 11. Global Healthcare API Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Service (2022-2032)
11.1.2. Market Revenue and Forecast, by Deployment Model (2022-2032)
11.1.3. Market Revenue and Forecast, by End-Use (2022-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Service (2022-2032)
11.1.4.2. Market Revenue and Forecast, by Deployment Model (2022-2032)
11.1.4.3. Market Revenue and Forecast, by End-Use (2022-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Service (2022-2032)
11.1.5.2. Market Revenue and Forecast, by Deployment Model (2022-2032)
11.1.5.3. Market Revenue and Forecast, by End-Use (2022-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Service (2022-2032)
11.2.2. Market Revenue and Forecast, by Deployment Model (2022-2032)
11.2.3. Market Revenue and Forecast, by End-Use (2022-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Service (2022-2032)
11.2.4.2. Market Revenue and Forecast, by Deployment Model (2022-2032)
11.2.4.3. Market Revenue and Forecast, by End-Use (2022-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Service (2022-2032)
11.2.5.2. Market Revenue and Forecast, by Deployment Model (2022-2032)
11.2.5.3. Market Revenue and Forecast, by End-Use (2022-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Service (2022-2032)
11.2.6.2. Market Revenue and Forecast, by Deployment Model (2022-2032)
11.2.6.3. Market Revenue and Forecast, by End-Use (2022-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Service (2022-2032)
11.2.7.2. Market Revenue and Forecast, by Deployment Model (2022-2032)
11.2.7.3. Market Revenue and Forecast, by End-Use (2022-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Service (2022-2032)
11.3.2. Market Revenue and Forecast, by Deployment Model (2022-2032)
11.3.3. Market Revenue and Forecast, by End-Use (2022-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Service (2022-2032)
11.3.4.2. Market Revenue and Forecast, by Deployment Model (2022-2032)
11.3.4.3. Market Revenue and Forecast, by End-Use (2022-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Service (2022-2032)
11.3.5.2. Market Revenue and Forecast, by Deployment Model (2022-2032)
11.3.5.3. Market Revenue and Forecast, by End-Use (2022-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Service (2022-2032)
11.3.6.2. Market Revenue and Forecast, by Deployment Model (2022-2032)
11.3.6.3. Market Revenue and Forecast, by End-Use (2022-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Service (2022-2032)
11.3.7.2. Market Revenue and Forecast, by Deployment Model (2022-2032)
11.3.7.3. Market Revenue and Forecast, by End-Use (2022-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Service (2022-2032)
11.4.2. Market Revenue and Forecast, by Deployment Model (2022-2032)
11.4.3. Market Revenue and Forecast, by End-Use (2022-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Service (2022-2032)
11.4.4.2. Market Revenue and Forecast, by Deployment Model (2022-2032)
11.4.4.3. Market Revenue and Forecast, by End-Use (2022-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Service (2022-2032)
11.4.5.2. Market Revenue and Forecast, by Deployment Model (2022-2032)
11.4.5.3. Market Revenue and Forecast, by End-Use (2022-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Service (2022-2032)
11.4.6.2. Market Revenue and Forecast, by Deployment Model (2022-2032)
11.4.6.3. Market Revenue and Forecast, by End-Use (2022-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Service (2022-2032)
11.4.7.2. Market Revenue and Forecast, by Deployment Model (2022-2032)
11.4.7.3. Market Revenue and Forecast, by End-Use (2022-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Service (2022-2032)
11.5.2. Market Revenue and Forecast, by Deployment Model (2022-2032)
11.5.3. Market Revenue and Forecast, by End-Use (2022-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Service (2022-2032)
11.5.4.2. Market Revenue and Forecast, by Deployment Model (2022-2032)
11.5.4.3. Market Revenue and Forecast, by End-Use (2022-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Service (2022-2032)
11.5.5.2. Market Revenue and Forecast, by Deployment Model (2022-2032)
11.5.5.3. Market Revenue and Forecast, by End-Use (2022-2032)
Chapter 12. Company Profiles
12.1. Apple, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. General Electric
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. athenahealth, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Oracle
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Epic Systems Corporation
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. eClinicalWorks
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Allscripts Healthcare, LLC
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Greenway Health, LLC
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Practice Fusion, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Salesforce, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers